Dyne Therapeutics Inc Advancing FORCE in the Pursuit of Transformative Therapies Transcript
Hello, everyone. Welcome to today's webinar between PPMD and Dyne Therapeutics. I want to thank you all for joining us this afternoon. We're looking forward to this conversation where we can learn a little bit more about Dyne's FORCE platform in their Phase 1/2 clinical trial with DYNE-251, which is a product for those amenable to exon 51 skipping. Joining me today to walk through the presentation is Ash Dugar the Chief Medical Affairs Officer from Dyne, and we're also joined by Molly White, the VP, Global Head of Patient Advocacy at Dyne.
(Operator Instructions) And of course, we are recording this webinar. So if you have to step away or if you have friends or family members who this might be relevant to please feel free to share it with them. Typically we'll have us up some time likely next week for sharing.
But with that, we can get started for the talk today. So I'm going to hand it over to Ash. He's going to take us through the presentation.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |